최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기대한한방내과학회지 = The journal of internal Korean medicine, v.32 no.1, 2011년, pp.129 - 135
이진수 (경희대학교 한의과대학 임상종양학과) , 박형준 (경희대학교 한의과대학 임상종양학과) , 채진 (경희대학교 한의과대학 임상종양학과) , 김경석 (강동경희대학교병원 한방내과) , 정현식 (강동경희대학교병원 한방내과) , 이상헌 (강동경희대학교병원 한방내과) , 최원철 (경희대학교 한의과대학 임상종양학과) , 전성하 (강동경희대학교병원 혈액종양내과)
This report documents a case in which the administration of an herbal product, an extract of the lacquer tree, Rhus verniciflua Stokes, as sequential and concurrent treatment with chemotherapy was associated with a long term survival and good quality of life in a patient with metastatic non-small ce...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
핵심어 | 질문 | 논문에서 추출한 답변 |
---|---|---|
폐암의 특징은? | 폐암은 세계적으로 가장 흔한 암으로 한국을 포함한 전세계적으로 암으로 인한 사망 중 주요한 원인이 되고 있다1-2. 폐암 환자의 약 75%는 비소세포폐암이며, 나머지 25%는 소세포폐암이 차지한다3 . | |
폐암 환자의 비율은? | 폐암은 세계적으로 가장 흔한 암으로 한국을 포함한 전세계적으로 암으로 인한 사망 중 주요한 원인이 되고 있다1-2. 폐암 환자의 약 75%는 비소세포폐암이며, 나머지 25%는 소세포폐암이 차지한다3 . 비소세포폐암의 경우 약 50%가 수술이 불가능한 진행성 병기에서 진단되는 경우가 많은데, 이러한 경우에는 완치를 기대하기 힘들며, 항암화학요법을 통한 생명연장의 완화목적 치료가 주로 이루어지게 된다4. | |
본 연구에서 4기 폐암 환자의 생존기간은? | 환자는 현재까지 aRVS와 항암화학요법의 순차적, 그리고 병행적 치료의 방법으로 41개월의 매우 긴 생존기간을 보여주고 있다. 또한 현재 양호한 컨디션을 유지하고 있어 향후 질병이 진행했을 경우 적용 가능한 항암화학요법의 가능성 또한 있다는 점은 매우 고무적이다. |
Yoo KY. Cancer control activities in the Republic of Korea. Jpn J Clin Oncol. 2008;38:327-33.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. CA Cancer J Clin. Cancer statistics. 2008;58:71-96.
Stinchcombe TE SM. Considerations for second -line therapy of non-small cell lung cancer. Oncologist. 2008;13:28-36.
Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18:2095-103.
Schiller JH HD, Belani CP, Langer C, Sandler A, Krook J, Zhu J, et al; Eastern CooperativeOncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92-8.
Mok TS WY, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947-57.
Sandler A GR, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, at al. Paclitaxel -carboplatin alone or with bevacizumab for non -small-cell lung cancer. N Engl J Med. 2006;355:2542-50.
Shepherd FA RPJ, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, et al. National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123-32.
Ardizzoni A, Boni L, Tiseo M, Fossella FV, Schiller JH, Paesmans M, et al. CISCA (CISplatin versus CArboplatin) Meta-analysis Group. Cisplatinversus carboplatin-based chemotherapy in firstline treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst. 2007;99:847-57.
Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M. Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2004;22:3852-9.
Pirker R PJ, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, et al, FLEX Study Team. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet. 2009;273:1525-31.
Yoo HT RJ. Compendium of prescriptions from the countryside(Hyangyakjipseongbang). Seoul: Hangrimchulpansa; 1977, p. 1433-640.
Choi WC LJ, Lee EO et al. Study on antiangiogenic and antitumor activities of processed Rhus verniciflua Stokes extract. Korean J Oriental Physiol Pathol. 2006;20:1-5.
Kook SH SY, Chung SW, et al. Caspase-independent death of human osteosarcoma cells by flavonoids is driven by p53-mediated mitochondrial stress and nuclear translocation of AIF and endonuclease G. Apoptosis. 2007;12:1289-98.
Lee SH, Kim KS, Choi WC, Yoon SW. Successful outcome of advanced pulmonary adenocarcinoma with malignant pleural effusion by the standardized Rhus verniciflua stokes extract: a case study. Explore (NY). 2009;5:242-4.
Lee SK, Jung HS, Eo WK, Lee SY, Kim SH, Shim BS. Rhus verniciflua Stokes extract as a potential option for treatment of metastatic renal cell carcinoma: report of two cases. Ann Oncol. 2010;21:1383-5.
Lee SH, Choi WC, Kim KS, Park JW, Yoon SW. Shrinkage of gastric cancer in an elderly patient who received Rhus verniciflua Stokes extract. J Altern Complement Med. 2010;16:497-500.
Kim HR, Kim KS, Jung HS, Choi WC, Eo WK, Cheon SH. A case of recurred hepatocellular carcinoma refractory to doxorubicin after liver transplantation showing response to herbal medicine product, Rhus verniciflua Stokes extract. Integr Cancer Ther. 2010;9:100-4.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-47.
Richardson MA ST, Palmer JL, Greisinger A, Singletary SE. Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol. 2000;18:2505-14.
Socinski MA, Schell MJ, Peterman A, Bakri K, Yates S, Gitten R, et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-smallcell lung cancer. J Clin Oncol. 2002;20:1335-43.
Hanna N SF, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22(9):1589-97.
Chang MH AJ, Lee J, Kim KH, Park YH, Han J, Ahn MJ, et al. The efficacy of pemetrexed as a third-or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer. Lung Cancer. 2010;69:323-9.
Sun JM LK, Kim JH, Kim YJ, Yoon HI, Lee JH, Lee CT, et al. Efficacy and toxicity of pemetrexed as a third-line treatment for nonsmall cell lung cancer. Jpn J Clin Oncol. 2009;39:27-32.
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.